Netrin-1 & Hepatocellular Carcinoma HCC
HCC-Net
Netrin-1 in Hepatocellular Carcinoma: Pathology, Preclinical Targeting, and Definition of Eligibility Criteria for Phase 1 Trials
1 other identifier
observational
320
1 country
1
Brief Summary
Netrin-1 is a dependence receptor ligand participating in the pathology of several cancer types. It is up-regulated in chronic liver diseases, cirrhosis and HCC. We hypothesize that netrin-1 may play a detrimental role in HCC. The goal of this project is to characterize netrin-1 signals in HCC samples with ad hoc controls, to investigate the benefit of capturing netrin-1 in preclinical models of HCC and to try to define patients groups the most likely to benefit from this targeting approach in the clinic.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2019
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2019
CompletedFirst Submitted
Initial submission to the registry
February 19, 2021
CompletedFirst Posted
Study publicly available on registry
February 23, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedFebruary 23, 2021
February 1, 2021
2 years
February 19, 2021
February 19, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Netrin-1 expression patterns in HCC samples
Netrin-1 expression levels will be quantified by immunoblotting with ad hoc internal standards. Positivity threshold by IHC will be evaluated using ad hoc positive and negative control tissues. The densitometry approach will be used.
Outcome measure is to be performed after surgery of the tumors (at least 1 year later). It has no impact on the patient's care.
Study Arms (2)
Tumors (T) samples of various etiologies (HBV, HCV, NASH, alcool)
The combination of the Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool)
Non Tumors (NT) samples of various etiologies (HBV, HCV, NASH, alcool)
The combination of the Non Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool)
Interventions
Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion.
Eligibility Criteria
Both men and women, between 18 and 85 years of age, suffering from Hepatocellular Carcinoma.
You may qualify if:
- any patient suffering from HCC
- age \>18
- informed consent provided
You may not qualify if:
- \- absence of informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hepatogastroenterology service of the Croix-Rousse Hospital
Lyon, 69004, France
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 19, 2021
First Posted
February 23, 2021
Study Start
July 1, 2019
Primary Completion
June 30, 2021
Study Completion
December 31, 2022
Last Updated
February 23, 2021
Record last verified: 2021-02